Oculis Holding AG Announces Pricing of $100 Million Underwritten Offering

ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) —

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses (the “Offering”).

Expanding Innovation in the Biopharmaceutical Industry

Oculis Holding AG’s recent announcement of the pricing of its underwritten offering marks a significant milestone for the company as it seeks to address unmet medical needs in ophthalmic and neuro-ophthalmic diseases. With a focus on innovation and a commitment to improving patient outcomes, Oculis is poised to make a meaningful impact in the biopharmaceutical industry.

Professionally Driven and Profit Focused

Oculis Holding AG’s strategic approach to the underwritten offering reflects a commitment to achieving long-term success and profitability. By pricing its ordinary shares at $20.00 per share, the company is positioned to secure $100 million in gross proceeds, providing a strong foundation for continued growth and development.

Impact on the Individual

For individuals, this announcement may signify potential advancements in the treatment of ophthalmic and neuro-ophthalmic diseases. With Oculis Holding AG’s focus on innovation, patients may have access to new and improved therapies that could enhance their quality of life and overall well-being.

Global Implications

On a global scale, Oculis Holding AG’s underwritten offering has the potential to shape the future of the biopharmaceutical industry. By addressing unmet medical needs and driving innovation, the company is setting a precedent for how biopharmaceutical companies can make a positive impact on a global scale.

Conclusion

In conclusion, Oculis Holding AG’s pricing of $100 million underwritten offering underscores the company’s commitment to innovation, profitability, and addressing unmet medical needs in the biopharmaceutical industry. With a focus on ophthalmic and neuro-ophthalmic diseases, Oculis is well-positioned to make a significant impact both at the individual level and on a global scale.